New York Implements Strategy to Reduce Prescription Drug Prices
The New York City Health Department oversees an annual budget of approximately billion, complemented by a similar contribution of billion to NYC Health + Hospitals, the public health care system that services over one million residents each year. However, these figures pale in comparison to the city’s largest health expenditure: more than billion allocated annually for employee and retiree health benefits. This significant financial commitment raises critical questions about whether public sector employees—including teachers, nurses, firefighters, and sanitation workers—are receiving the healthcare they require. Moreover, it prompts an examination of the overall value derived from this substantial spending.
In January, the city took a notable step towards managing health care costs by transitioning to a self-insured model for health benefits, thereby eliminating the previously employed middleman. Nevertheless, further measures are necessary to enhance healthcare access and reduce waste, particularly concerning prescription medications.
The NYC Employees PPO plan currently covers over 1.2 million individuals, including employees, retirees, and their dependents. A collaboration with New York State could broaden this scope to roughly 2.5 million individuals, potentially surpassing most private employer groups nationwide. This collective demographic offers the city substantial leverage in negotiating favorable pricing and terms for pharmaceuticals.
To maximize this purchasing power, the city could implement three strategic actions. Firstly, a comprehensive review of the existing contract with Prime Therapeutics, the private pharmacy benefit manager for enrollees, is essential to ensure equitable pricing. The contract must explicitly ban practices such as “spread pricing,” which permits the PBM to profit from disparities between pharmacy rates and the fees charged to the city.
Secondly, the Office of Healthcare Accountability within the Health Department should be tasked with designing innovative payment models for high-demand medications. Key treatments, including antivirals for hepatitis C, HIV prevention medicines, and GLP-1 medications like semaglutide (Ozempic), could dramatically improve public health if access is expanded.
Thirdly, the city should consider establishing a public pharmacy benefit model, similar to its recent move to eliminate for-profit intermediaries in health benefits administration. By doing so, New York City could ensure that drug rebates and negotiated savings directly benefit the municipality and its residents rather than a private entity.
Several states have begun exploring collaborative initiatives, such as ArrayRx, to manage PBM services, although these still involve private sector contracting. The NYC Commission on Government Efficiency is currently evaluating potential financial savings and addressing any legal challenges related to these endeavors.
There are compelling testimonies from clinical practice, including instances where patients have deferred purchasing necessary medications due to financial constraints. These delays often result in more comprehensive and costly medical interventions later on. By employing rigorous contracting standards, leveraging collective purchasing power, and fostering innovation in healthcare delivery, New York City can lead the way in creating a healthcare model that emphasizes both affordability and accessibility for its residents.
Media News Source
